5243962025-07-012025-09-305243962025-09-305243962025-03-315243962025-04-012025-09-305243962025-07-012025-09-30in-capmkt:OtherExpenses1Member5243962025-07-012025-09-30in-capmkt:OtherExpenses2Member5243962025-07-012025-09-30in-capmkt:OtherExpenses3Member5243962025-04-012025-09-30in-capmkt:OtherExpenses1Member5243962025-04-012025-09-30in-capmkt:OtherExpenses2Member5243962025-04-012025-09-30in-capmkt:OtherExpenses3Member5243962025-07-012025-09-30in-capmkt:ReportableSegments1Member5243962025-07-012025-09-30in-capmkt:ReportableSegments2Member5243962025-04-012025-09-30in-capmkt:ReportableSegments1Member5243962025-04-012025-09-30in-capmkt:ReportableSegments2Member5243962025-07-012025-09-30in-capmkt:ReportableSegments1Member5243962025-07-012025-09-30in-capmkt:ReportableSegments2Member5243962025-04-012025-09-30in-capmkt:ReportableSegments1Member5243962025-04-012025-09-30in-capmkt:ReportableSegments2Member5243962025-07-012025-09-30in-capmkt:ReportableSegments1Member5243962025-09-30in-capmkt:ReportableSegments1Member5243962025-07-012025-09-30in-capmkt:ReportableSegments2Member5243962025-09-30in-capmkt:ReportableSegments2Member5243962025-07-012025-09-30in-capmkt:ReportableSegments1Member5243962025-09-30in-capmkt:ReportableSegments1Member5243962025-07-012025-09-30in-capmkt:ReportableSegments2Member5243962025-09-30in-capmkt:ReportableSegments2Member5243962025-07-012025-09-30RelatedPartyTransactionDomain15243962025-06-30RelatedPartyTransactionDomain15243962025-09-30RelatedPartyTransactionDomain15243962025-07-012025-09-30RelatedPartyTransactionDomain25243962025-06-30RelatedPartyTransactionDomain25243962025-09-30RelatedPartyTransactionDomain25243962025-07-012025-09-30RelatedPartyTransactionDomain35243962025-06-30RelatedPartyTransactionDomain35243962025-09-30RelatedPartyTransactionDomain35243962025-07-012025-09-30RelatedPartyTransactionDomain45243962025-06-30RelatedPartyTransactionDomain45243962025-09-30RelatedPartyTransactionDomain45243962025-07-012025-09-30RelatedPartyTransactionDomain55243962025-06-30RelatedPartyTransactionDomain55243962025-09-30RelatedPartyTransactionDomain55243962025-07-012025-09-30RelatedPartyTransactionDomain65243962025-06-30RelatedPartyTransactionDomain65243962025-09-30RelatedPartyTransactionDomain65243962025-07-012025-09-30RelatedPartyTransactionDomain75243962025-06-30RelatedPartyTransactionDomain75243962025-09-30RelatedPartyTransactionDomain75243962025-07-012025-09-30RelatedPartyTransactionDomain85243962025-06-30RelatedPartyTransactionDomain85243962025-09-30RelatedPartyTransactionDomain85243962025-07-012025-09-30RelatedPartyTransactionDomain95243962025-06-30RelatedPartyTransactionDomain95243962025-09-30RelatedPartyTransactionDomain95243962025-07-012025-09-30RelatedPartyTransactionDomain105243962025-06-30RelatedPartyTransactionDomain105243962025-09-30RelatedPartyTransactionDomain10iso4217:INRxbrli:pureiso4217:INRxbrli:shares524396BIOFILCHEMNOTLISTEDINE829A01014BIOFIL CHEMICALS & PHARMACEUTICALS LIMITEDMain BoardEquity2025-04-012026-03-312025-11-132025-11-07INRLakhsQuarterlySecond quarterMulti segment2025-11-1316:45:002025-11-1318:30:00trueCash Flow IndirectNot applicabletruetrueNANAfalsetrue2025-02-11https://mufmerinmovawwcvpkjx.supabase.co/storage/v1/object/public/investor_documents/investor_documents/1745325585391-Policy%20on%20dealing%20with%20related%20party%20transactions_11.02.2025.pdffalsefalseNA2025-07-012025-09-30UnauditedStandalone1354080006340001360420001181900070746000483800001780000100066000015390001349250001117000011170002810000281000083600000008360000836000162738000100.050.05000.050.051. The above Unaudited financial results of "the company" for the 2nd quarter and half year ended 30th September 2025 have been reviewed by the Audit committee and subsequently approved by the Board of Directors in their meeting held on Thursday, 13th Day of November 2025. The above results for the 2nd quarter and half year ended 30th September, 2025 have been reviewed by the statutory auditors of the company in terms of Regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 who have expressed an unmodified opinion. The company’s management has exercised necessary due diligence to ensure that the unaudited financial result provide a true and fair view of its affairs. <BR> <BR> 2. The Statement of Assets & Liabilities as at September 30, 2025 is annexed with the financial results along with the Cash Flow Statements. <BR> <BR> 3. This above unaudited Financial Results have been prepared in accordance with the guidelines issued by the Securities and Exchange Board of India (SEBI) and the Companies (Indian Accounting Standards) Rules, 2015 (Ind-AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable. <BR> <BR> 4. The Company has reported segment wise information as per Indian Accounting Standard (Ind AS-108). The Operations of the Company are conducted within India, there is no separate reportable geographical segment and the company reported the following business segments <BR> a. Pharma Product <BR> b. Chemicals Division <BR> <BR> 5. The figures of the previous period / year have been re-stated/ re-grouped / re-arranged/ reclassified and / or recasted wherever found necessary. <BR> <BR> 6.     The aforesaid un-Audited financial Results will be uploaded on the Company’s website www.biofilgroup.net and will also be available on the websites of the Stock exchanges i.e. www.bseindia.com and www.nseindia.com for the benefit of shareholders and investors.2025-04-012025-09-30UnauditedStandalone1997340002895400022868800023533000168152000-14110003884000940001320000437500019994700028741000028741000379600003796000024945000000024945000024945000162738000101.531.53001.531.53Manufacturing Expenses767000Administrative Expenses603000Selling and Distribution Expenses169000Manufacturing Expenses1964000Administrative Expenses2116000Selling and Distribution Expenses29500069450000000006945000034825000040770000023440001250000041129400038067000484186000553636000162738000503050002130430002130430000003312000331200020000003333410003333410003335410003740000337281000340593000553636000Pharma Unit121447000Chemicals Division13961000Pharma Unit169922000Chemicals Division29812000135408000199734000135408000199734000Pharma Unit722000Chemicals Division46000Pharma Unit27697000Chemicals Division78300076800028480000-349000-26100000111700028741000Pharma Unit384296000Chemicals Division1693400005536360000553636000Pharma Unit312352000Chemicals Division26438000338790000033879000094000-1411000-245500000-316480000000234640000-178600001320000000000000000-2811800000-62635000-3389400000017590000-35653000000000004150000070500000000000000000000050600000413010000000000004513000009400000-460700010410000104100025530003594000000000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******CYANO PHARMA PVT LTD******Directors and their relatives are Directors and Members in the CompanySale of goods or services350000000Approved by Audit Committee and also from members158510001303800017535000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******CYANO PHARMA PVT LTD******Directors and their relatives are Directors and Members in the CompanySale of fixed assets21500000Also Approved by Members dated 21.03.20252150000000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******CYANO PHARMA PVT LTD******Directors and their relatives are Directors and Members in the CompanyPurchase of goods or services350000000Approved by Audit Committee and also from members58200007840900057509000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******FORMO PLAST PVT LTD******Directors and their relatives are Directors and Members in the CompanySale of fixed assets20000000Also Approved by Members dated 21.03.20252000000000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******MID INDIA PHARMACEUTICALS PVT LTD******Directors and their relatives are Directors and Members in the CompanyLoan10000000Approved by Audit Committee400000040000000Loan0.093UnsecuredBusiness Purpose (Loan Taken)Repayment of Loan taken during the periodBIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******MID INDIA PHARMACEUTICALS PVT LTD******Directors and their relatives are Directors and Members in the CompanyAny other transactionInterest Paid603000Approved by Audit Committee6030005130000Interest paid during the period including Rs. 0.90 Lacs during the half yearBIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******KETAN SHAH******Person belong to Promoter and Chairman and Managing Director (KMP) of the CompanyRemuneration3000000Approved by Audit Committee and also from members870000103000116000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******APOORV JAIN******Company Secretary and Compliance Officer of the CompanyRemuneration600000Approved by Audit Committee232000045000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******PAWAN SINGH RAJPUT******Chief Financial Officer of the CompanyRemuneration400000Approved by Audit Committee1500001700017000BIOFIL CHEMICALS AND PHARMACEUTICALS LTD.******Rohan Shah******Person belong to Promoter Group of the CompanyAny other transactionSalary1200000Approved by Audit Committee50000008800069526000